Clinical evaluation reveals avoidable reasons for tPA exclusion in 18% of acute ischemic stroke cases, suggesting better intrahospital coordination can improve access.
Despite evidence for the efficacy of thrombolytic therapy in acute ischemic stroke, only 1 to 7% of patients receive this therapy. The authors sought to determine the reasons for exclusion from tissue plasminogen activator (tPA) in an acute setting and found avoidable causes in 18% of patients. Improvements in intrahospital coordination would increase the number of patients who might benefit from tPA treatment at the authors' center.
No takes yet. Share an insight, caveat, or question.
A 2005 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: